Optimizing First-Line Therapies for Metastatic Colorectal Cancer

Metastatic colorectal cancer (mCRC) remains a leading cause of cancer mortality, driving continual refinement of first-line treatment strategies. Progress in molecular profiling has enabled stratification by RAS and BRAF mutational status, guiding the choice between chemotherapy backbones and targeted agents. Regimen intensification, such as triplet chemotherapy, and the addition of monoclonal antibodies against epidermal growth factor receptor (EGFR) or vascular endothelial growth factor (VEGF) receptors have been evaluated to maximise tumour shrinkage and facilitate secondary resection. Patient selection by primary tumour location, molecular biomarkers and performance status permits individualised therapy, while integrated supportive measures aim to preserve nutritional status and quality of life. The overarching goal is to balance efficacy, toxicity and conversion to resectability, thus improving progression-free and overall survival on a global scale.

Research from Nature Portfolio

Recent studies have explored the comparative efficacy of intensified chemotherapy regimens combined with EGFR-targeted therapy versus anti-VEGF treatment in RAS wild-type mCRC. A randomised phase II trial assessed modified FOLFOXIRI plus weekly cetuximab against bevacizumab added to the same backbone. While overall response rates and progression-free survival were similar, depth of tumour shrinkage was significantly greater with cetuximab. Subgroup analyses indicated a pronounced benefit in patients with left-sided and RAS/BRAF wild-type tumours, including improved median progression-free and overall survival. Safety profiles were manageable, suggesting that tailored intensification of first-line therapy can enhance early tumour control without compromising tolerability.

Optimizing First-Line Therapies for Metastatic Colorectal Cancer publication trend

The graph below shows the total number of articles in optimizing first-line therapies for metastatic colorectal cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Metastatic colorectal cancer (mCRC): colorectal carcinoma that has spread beyond the primary site to distant organs.

FOLFOXIRI: chemotherapy regimen combining 5-fluorouracil, leucovorin, oxaliplatin and irinotecan.

Cetuximab: monoclonal antibody targeting the epidermal growth factor receptor (EGFR).

Bevacizumab: monoclonal antibody inhibiting vascular endothelial growth factor (VEGF).

RAS wild-type: tumour cells without activating mutations in KRAS or NRAS genes, predictive of response to EGFR inhibitors.

Progression-free survival (PFS): time from treatment initiation to disease progression or death.

Overall survival (OS): time from treatment initiation to death from any cause.

Objective response rate (ORR): proportion of patients achieving predefined tumour shrinkage.

Depth of response (DpR): maximal percentage reduction in tumour size from baseline.

Primary tumour location: anatomical side (left or right) of the original colorectal lesion, influencing therapeutic responsiveness.

References

1. Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial. Nature Communications (2024).
2. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. British Journal of Cancer (2020).
3. First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer (2019).